Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Decreases By 60.4%

Bone Biologics Co. (NASDAQ:BBLG) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 76,500 shares, a decrease of 60.4% from the February 28th total of 193,300 shares. Based on an average daily volume of 211,100 shares, the short-interest ratio is currently 0.4 days. Approximately 14.3% of the company’s stock are sold short.

Bone Biologics Stock Down 2.6 %

Shares of NASDAQ:BBLG traded down $0.02 during trading on Friday, hitting $0.82. 24,300 shares of the company were exchanged, compared to its average volume of 1,389,644. The firm’s 50 day moving average price is $0.96 and its 200-day moving average price is $1.24. Bone Biologics has a 12-month low of $0.71 and a 12-month high of $4.25.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.